Peregrine Pharmaceuticals reported $141.8M in Loan Capital for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Amgen AMGN:US $ 35705M 305M
AstraZeneca AZN:LN 2229663.86M 36335.94M
Bristol Myers Squibb BMY:US $ 37107M 343M
Celldex Therapeutics CLDX:US $ 0M 0M
Chemocentryx CCXI:US $ 4M 0.55M
Eli Lilly And LLY:US $ 14692M 460.9M
GlaxoSmithKline GSK:LN 1878400M 1044200M
Karyopharm Therapeutics KPTI:US $ 302.69M 202K
Macrogenics MGNX:US $ 0 0
Mannkind MNKD:US $ 366.99M 8.14M
Novartis NOVN:VX SF 23784M 589M
Peregrine Pharmaceuticals PPHM:US $ 141.8M 0.13M
Repligen RGEN:US $ 0M 0M
Xencor XNCR:US $ 0M 0M